Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078193 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Belatacept in Reducing DSA
A Phase 4 study, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT02078193: Completed Phase 4 study, sponsored by East Carolina University.
NCT02078193 is a Phase 4 study that has completed, run by East Carolina University. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02078193, a Phase 4 study, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).
Primary Outcome
DSA levels will be measured using microbeads coated with Class I or Class II human leukocyte antigens (HLA) and read using a Luminex flow cytometer. Participants will be converted from their current Mycophenolate Mofetil (MMF) to once a month infusions of Belatacept.
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
What the finished NCT02078193 record still lists
NCT02078193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT02078193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02078193 about?
NCT02078193 is a clinical study titled "Efficacy of Belatacept in Reducing DSA". The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).
What is the current status of trial NCT02078193?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2013-11. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02078193?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT02078193?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02078193's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia